| P2093 | author name string | John Doupis | |
| | Spyridoula Glykofridi | |
| | Vasileios Andrianesis | |
| P2860 | cites work | T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes | Q78238839 |
| | Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis | Q80984741 |
| | Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects | Q84856868 |
| | Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects | Q85428079 |
| | Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration | Q85674886 |
| | Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial | Q87809056 |
| | The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat | Q88214242 |
| | The fundamental drivers of the obesity epidemic | Q22242406 |
| | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| | Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial | Q27301948 |
| | SGLT2 Inhibitors May Predispose to Ketoacidosis | Q28081173 |
| | The sodium/glucose cotransport family SLC5 | Q28204259 |
| | Active sugar transport in health and disease | Q28283298 |
| | Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models | Q28732080 |
| | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar | Q33612741 |
| | The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? | Q33778918 |
| | Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus | Q33785128 |
| | Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 |
| | Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial | Q34153496 |
| | A Review on the Relationship between SGLT2 Inhibitors and Cancer. | Q34181385 |
| | Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 |
| | Tofogliflozin: first global approval | Q34420901 |
| | SGLT2 mediates glucose reabsorption in the early proximal tubule. | Q34457264 |
| | Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density | Q34535894 |
| | Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? | Q34579919 |
| | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Q34646948 |
| | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 |
| | Molecular physiology of sodium-glucose cotransporters | Q34724942 |
| | Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus | Q34876148 |
| | Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials | Q35068181 |
| | Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial | Q35179843 |
| | Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose | Q35184196 |
| | Renal hyperfiltration related to diabetes mellitus and obesity in human disease | Q35673442 |
| | Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. | Q35968414 |
| | Phlorizin: a review | Q35995949 |
| | Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study' | Q36073447 |
| | Glomerular hyperfiltration and renal disease progression in type 2 diabetes | Q36249519 |
| | Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus | Q36312587 |
| | Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update | Q36435496 |
| | Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes | Q36782790 |
| | Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Q36845771 |
| | Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes | Q36926197 |
| | Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells | Q36977366 |
| | Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study | Q37022903 |
| | Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. | Q37219076 |
| | A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment | Q37319128 |
| | Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes | Q37331262 |
| | Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. | Q37387010 |
| | Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 |
| | SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. | Q37575455 |
| | Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor | Q37589626 |
| | Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. | Q37645623 |
| | Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes | Q37679810 |
| | Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control | Q37679893 |
| | The protein family of glucose transport facilitators: It's not only about glucose after all. | Q37704272 |
| | The clinical significance of hyperfiltration in diabetes | Q37760090 |
| | Biology of human sodium glucose transporters | Q37870037 |
| | The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. | Q37940036 |
| | SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus | Q38077305 |
| | Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors | Q38196149 |
| | Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport | Q38201162 |
| | Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes | Q38205581 |
| | Arterial stiffness: insights from Framingham and Iceland | Q38282226 |
| | Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus | Q38439475 |
| | Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells | Q40276214 |
| | The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies | Q40325056 |
| | Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes | Q40328483 |
| | The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells | Q40561968 |
| | Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. | Q41015653 |
| | TGF-beta 1 dissociates human proximal tubule cell growth and Na(+)-H+ exchange activity. | Q42455935 |
| | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial | Q42977455 |
| | Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus | Q43199877 |
| | Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. | Q43755014 |
| | Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus | Q44007780 |
| | Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 |
| | Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin | Q44653784 |
| | Long-term outcome of renal glucosuria type 0: the original patient and his natural history | Q45010378 |
| | Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes | Q45348074 |
| | Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia | Q45442620 |
| | Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study | Q46223922 |
| | PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose | Q46484275 |
| | Screening for kidney disease in adults with diabetes | Q46570776 |
| | Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 |
| | The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. | Q46847425 |
| | Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor | Q46986653 |
| | Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment | Q47998377 |
| | Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. | Q50448714 |
| | Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 |
| | Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. | Q51337136 |
| | Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. | Q51362851 |
| | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Q51372081 |
| | Differences in active and passive glucose transport along the proximal nephron | Q52734694 |
| | Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 |
| | Pathologic classification of diabetic nephropathy. | Q55052603 |
| | Luseogliflozin: First Global Approval | Q57485821 |
| | Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0) | Q68986451 |
| | Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs | Q69490075 |
| | Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity | Q70640377 |
| | Glomerular hemodynamics in experimental diabetes mellitus | Q70801958 |
| | Is renal glycosuria a benign condition? | Q71153660 |
| | The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy | Q72007027 |
| | Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies | Q72925253 |
| | Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption | Q73253331 |
| P433 | issue | 5-6 | |
| P304 | page(s) | 212-228 | |
| P577 | publication date | 2016-11-11 | |
| P1433 | published in | Therapeutic advances in endocrinology and metabolism | Q26853790 |
| P1476 | title | The renal effects of SGLT2 inhibitors and a mini-review of the literature | |
| P478 | volume | 7 | |